- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Maple Grove Today
By the People, for the People
VDYNE Receives FDA Approval for Tricuspid Valve Trial
The medical device company will initiate a pivotal study of its transcatheter tricuspid valve repair system.
Apr. 1, 2026 at 3:07pm
Got story updates? Submit your updates here. ›
VDYNE, a medical device company, has received approval from the U.S. Food and Drug Administration (FDA) to begin the TRIVITA1 IDE pivotal trial of its transcatheter tricuspid valve repair system. The trial will evaluate the safety and effectiveness of VDYNE's device in treating tricuspid valve regurgitation, a common heart condition.
Why it matters
Tricuspid valve regurgitation is a significant health issue that can lead to heart failure if left untreated. VDYNE's device represents a potential new minimally invasive treatment option for patients, which could improve outcomes and quality of life compared to traditional open-heart surgery.
The details
The TRIVITA1 IDE pivotal trial will enroll up to 500 patients at multiple clinical sites across the United States. The trial will assess the safety and effectiveness of VDYNE's transcatheter tricuspid valve repair system in treating severe, symptomatic tricuspid regurgitation. The device is designed to be implanted using a minimally invasive, catheter-based procedure.
- VDYNE received FDA approval to initiate the TRIVITA1 IDE pivotal trial on April 1, 2026.
The players
VDYNE
A medical device company that has developed a transcatheter tricuspid valve repair system.
What’s next
The TRIVITA1 IDE pivotal trial is expected to begin enrolling patients in the coming months, with results anticipated in the next 2-3 years.
The takeaway
The FDA approval of VDYNE's pivotal trial represents a significant milestone in the development of new minimally invasive treatments for tricuspid valve regurgitation, a condition that can have serious health consequences if left untreated.
